Marianne is a principal at the Novartis Venture Fund in Basel, Switzerland. Prior to joining NVF, she worked in Novartis Global Drug Development and, before that, in the pre-clinical safety department at the Novartis Institutes of Biomedical Research, where she led teams delivering health authority-required and non-routine safety assessments for early and late-stage programs across many therapeutic areas. Concurrently, she supported the Novartis BD&L search & evaluation team, and spearheaded collaborations with biotechnology companies and academia for development of innovative in vitro/in vivo systems.
Marianne received her MSc in biochemistry from the University of Oslo and her PhD in molecular biology, cell biology and biophysics from a joint program between European Molecular Biology Laboratories and the University of Oslo.
Contact
T +31 85 800 8550
info@tagworkspharma.com
Address
Tagworks Pharmaceuticals BV
Toernooiveld 1
6525 ED Nijmegen
The Netherlands
Stay updated
© Tagworks Pharmaceuticals, 2023 | Terms of use | Design by Ape to Zebra